Oct 23, 2026 · 1h 4m
AI challenges biotech’s old company model
Episode 200 - October 23, 2026
The episode connects weak market sentiment and difficult financing with a deeper question: whether AI will change how biotech companies are built and led.
- 1Biotech’s bearish market reflects valuation pressure, trading dynamics, and the sector’s persistent difficulty turning science into durable returns.
- 2Silence Therapeutics’ acquisition illustrates how biotech leadership must navigate scientific risk, company-building, and uncertain outcomes.
- 3AI could redistribute biotech’s core functions, allowing smaller teams to design drugs, choose targets, and access development infrastructure externally.
Don't miss
Ali Mortazavi argues that AI and distributed development tools could make the conventional definition of a biotech company obsolete.
The brief
Biotech Hangout marks its 200th episode by looking back on five years of industry debate, then turning to a sector facing weak sentiment and persistent market-structure pressures.
The panel uses Moderna’s stock decline, the “biotech woodchipper,” and investor sentiment to examine how valuation, trading dynamics, and the difficulty of drug development shape the market.
Ali Mortazavi recounts Silence Therapeutics’ long path through RNAi challenges to its acquisition by Merck KGaA, offering a compressed case study in biotech company-building.
The conversation asks whether AI will reduce the need for traditional biotech CEOs, as software, distributed teams, and external partners make the boundaries of a biotech company less clear.
Alongside M&A, China deals, public-facing executives, and scientific controversies, the panel considers what biotech might look like when the show reaches its 2031 horizon.
What was said on this episode
30 statements · 25 positive · 3 negative · 2 neutral
Market expectations for Moderna’s cancer vaccine became exceptionally high.
“the amount of hope that's been pumped into this um story by the market um for the cancer vaccine is incredible”
Listen at 6:48
Moderna’s valuation had reached a level requiring near-perfect execution.
“you needed absolute perfection”
Listen at 7:41
Moderna’s stock remained above levels implied by the known trial success.
“this is clearly above what people thought this could do”
Listen at 10:46
Moderna’s cancer vaccine is more likely to become a major commercial product after the data.
“is this going to be a big seller for the companies clearly today now that we know the data it's a stronger yes”
Listen at 11:13
Biotech sector fundamentals remain strong despite bearish trading conditions.
“the fundamentals still seem really, really strong”
Listen at 13:20
Biotech is increasingly profitable, revenue-generating, and attractive to generalist investors.
“the sector itself is incredibly well positioned, increasingly profitable, increasingly revenue generating, increasingly appealing”
Listen at 13:32
Dario or Anthropic will eventually enter or transform pharmaceuticals.
“Dario or Anthropic would eventually experience pharma”
Listen at 14:53
Moderna’s recent price movements may have been driven mainly by market technicals, not fundamental value.
“it was entirely technical explanation for what had happened that had relatively little to do with either Moderna's actual value or anybody else's actual value”
Listen at 16:21
Structural trading dynamics may currently affect biotech valuations more than fundamentals.
“the structural issues are potentially more of an impact than the fundamental issues”
Listen at 19:01
The biotech market will resume a healthier trajectory after current difficulties.
“I'm predicting that we'll resume with kind of a healthy market”
Listen at 22:33
Biotech sector fundamentals are exceptionally strong despite external volatility.
“The fundamentals of the sector are phenomenal”
Listen at 24:41
Pharmaceutical companies are replenishing pipelines ahead of an unusually large patent-expiration wave.
“pharma companies are continuing to replenish their pipelines ahead of an unprecedented patent cliff”
Listen at 26:31
Biotech progress is driven primarily by incremental work from operational teams.
“it's an industry that's a game of inches propelled by the people on the ground doing the work”
Listen at 36:22
The biotech market has delivered exceptionally strong performance year to date.
“the XBI started the year at 108, it's at 150. By any measure, this is one of the best biotech markets of all time”
Listen at 45:01
Tango’s PRMT5 inhibitor showed an 82% response rate and 88% nine-month non-progression rate.
“82% response rate and 88% non-progression rate at nine months in very refractory third and fourth line pancreatic cancer patients”
Listen at 49:06
Tango’s pancreatic-cancer data ranks among the strongest oncology data Eric has seen.
“this is perhaps some of the best data I've ever seen covering the oncology space for many, many years”
Listen at 49:17
Tango’s share-price decline is temporary within a longer-term positive trajectory.
“this is a short-term blip on an otherwise long-term positive trajectory”
Listen at 49:50
Higher launch prices have helped biotech companies become profitable and more investable.
“that's actually changed quite dramatically thanks to Much higher launch prices, companies vaulting into profitability in the sector”
Listen at 55:11
Biotech innovation will continue producing major advances absent restrictive drug-pricing rhetoric.
“it's just going to be an incredible ride”
Listen at 55:38
Oncology will make substantial progress against difficult diseases including GBM and smaller indications.
“oncology would be again solving the diseases that they are difficult gbm potentially some of the smaller indications”
Listen at 56:15
Future oncology advances will shift outcomes toward living with cancer rather than dying from it.
“a lot of people living with cancer as opposed to dying of it”
Listen at 56:26
Neurological diseases will eventually become treatable through advances in neuroscience.
“neuroscience i'm really looking forward to neurological diseases being finally cracked open and treated”
Listen at 56:30
“AI is not going to live up to the current hype fully”
Listen at 57:44
Genetic medicines will achieve commercial success.
“genetic medicines are actually going to be successful, commercially successful”
Listen at 58:39
Commercial success in genetic medicines will emerge first through AATD and Beam’s program.
“I think it's going to happen first with AATD and Beam's program”
Listen at 58:54
“I hope we're talking about the meteoric rise of Roivant”
Listen at 59:21
AI will transform biotech substantially by 2031.
“AI is about to change biotech in an enormous way in 2031”
Listen at 59:27
Brain-shuttle technologies will revolutionize neuroscience.
“brain shuttle technologies are going to revolutionize neuroscience”
Listen at 1:00:38
Degrader drugs will become the next major medicine class.
“I think degraders are going to be the next mega class of medicines”
Listen at 1:01:00
AI-enabled biotech infrastructure may make clinical trials broadly accessible.
“almost anyone can do a clinical trial”
Listen at 1:02:24
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.